CU-20401

CU-20401 is a recombinant mutant collagenase developed by Cutia Therapeutics for the reduction of localized subcutaneous fat, particularly in conditions such as submental fat (SMF) accumulation. It is administered via subcutaneous injection. The drug acts selectively on the extracellular matrix attached to adipose tissue, degrading collagen in the subcutaneous fat layer and inducing apoptosis of adipocytes, which leads to a reduction in local fat deposits. CU-20401 has been engineered to have mild catalytic activity compared to wild-type collagenases, aiming to minimize side effects such as bruising and pain commonly associated with other treatments like deoxycholic acid-based solutions. Clinical trials have demonstrated promising safety and efficacy profiles for reducing excessive adipose accumulation[1][4][5][6][8].

Other names

recombinant mutant collagenase